Data showing high implant survival rate for Episealer® accepted for publication
Episurf Medical (Nasdaq: EPIS B) today announces that post-market surveillance survival data for the Episealer® Knee implant has been compiled and accepted for scientific publication in the peer-reviewed journal Surgical Technology International. The data shows a cumulative survival rate of >96% over 7 years. The publication, Patient-specific implants for focal cartilage lesions in the knee: implant survivorship analysis up to seven years post-implantation, by L. Ryd, K. Flodström and M. T. Manley focuses on survival data for 682 Episealer® knee implants implanted between 2012 and 2020.
"This publication on the implant survival status of the Episealer® device merits some significance. First, this is a report on all implants so far delivered at the date of the report, i.e. these results are representative for, not the few specially interested clinics, but for an entire cohort of surgeons. Secondly, the number of revisions is conspicuously low, on par with the best TKA-designs in the Swedish Knee Registry. Finally, and perhaps most importantly, all implant revisions have so far occurred before 30 months post-op. This means that the inappropriate cases - they exist in all types of surgery - fall out early. Our hypothesis is, that having passed 30 months, these implants may last for a very long time” says Pål Ryfors, CEO Episurf Medical.
This is the fifth peer-reviewed clinical article on the Episealer® knee implant accepted for publication, of which three have been accepted in 2020. Since before, there are five pre-clinical papers published.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 09.40 CET on 15 December 2020.
Tags: